Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • NCI-CCC Breast Tumor Board Question • Breast Cancer, Metastatic
For patients with metastatic HER2-null (IHC 0+) breast cancer, do you offer trastuzumab deruxtecan based on the DAISY trial results?
Answer from: Medical Oncologist at Academic Institution
DAISY trial was a small trial and the outcome was hypothesis-generating rather than practice-changing. With that said, I offer trastuzumab deruxtecan to patients with metastatic breast cancer even if HER2 IHC on biopsy of metastatic disease was 0 but historically, their primary tumor tested at least...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
This question begs another update for the ASCO/CAP guidelines on the description of HER2 positivity/negativity and/or HER2 low expressors. The first ASCO/CAP guidelines on HER2 interpretation in breast cancer were released in 2007 and subsequently updated in 2013 and 2018. The most recent updated 20...
Answer from: Medical Oncologist at Community Practice
Breast cancer evolution and tumor progression are governed by the complex interactions between steroid receptor (ER/PR) and growth factor receptor (HER) signaling highlighting the intimate crosstalk between the hormone and HER family signaling pathways as a contributor of resistance to therapy which...